Please login to the form below

Not currently logged in
Email:
Password:

Baxter reveals collaboration for next-generation home haemodialysis

Baxter collaborates with DEKA Research & Development and HHD for the development of a next-generation home haemodialysis machine

Baxter International has collaborated with DEKA Research & Development and HHD for the development of a next-generation home haemodialysis machine.

Baxter and DEKA have collaborated on other successful products in the past, most notably on the design and development of Baxter's HomeChoice automated peritoneal dialysis machine.

Per the collaboration agreement, Baxter has purchased an option to acquire the assets of HHD and will fund DEKA's related R&D activities. Baxter may also make future royalty payments to DEKA. Baxter expects to record a special net pre-tax charge of up to USD 25m (USD 0.04 per diluted share) for in-process R&D associated with this transaction in Q3 2007.

Bruce McGillivray, president of Baxter's renal business, said: "This collaboration highlights Baxter's ongoing commitment to innovation in end-stage renal disease (ESRD) treatment. Our global leadership in home dialysis therapy, combined with DEKA's new medical product development expertise, will allow us to advance this promising technology at a faster pace."

7th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics